Paul Moore

Company: MacroGenics

Job title: VP, Cell Biology and Immunology

Bio:

25 years of experience working in biotech, coordinating efforts focused on the discovery and development of novel biologic-based therapies. At MacroGenics, leads a research group dedicated to the discovery, preclinical development and clinical translational biology of antibody-based therapeutics including Fc-optimized mAbs and bispecifics for cancer or autoimmune disease through harnessing of the host immune system. Began biotechnology career at HGS, where directed genomic-based target discovery programs and the preclinical development of various protein and mAb-based therapeutics. Notably these efforts led to the discovery of BLyS as a B-cell survival factor providing the basis for the development of Benlysta for the treatment for lupus. Obtained PhD from University of Glasgow and performed post-doctoral work at the Roche Institute of Molecular Biology; co-authored over 70 peer-reviewed manuscripts and 40 issued US patents.

Seminars:

Clinical and Translational Experience from a Phase I Clinical Study of Flotetuzumab, a CD123 x CD3 DART® Molecule, in Acute Myeloid Leukemia 4:15 pm

Flotetuzumab is designed to target T cells to kill CD123-expressing tumor cells present in acute myeloid leukemia (AML) and other hematologic malignancies In Phase I studies, flotetuzumab elicits anti-leukemic activity in relapse/refractory (R/R) AML patients with a dosing strategy optimized to potentially ameliorate cytokine release syndrome (CRS) Translational studies also demonstrate the emergence of an…Read more

day: Day Two